Metoclopramide and Homicidal Ideation: A Case Report and Literature Review

Psychosomatics

Volumn 52, Issue 5, 2011, Pages 403-409

  Surawski, Robert J ^b   Quinn, Davin K ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CLONAZEPAM; GLUCOSE; METOCLOPRAMIDE; SERTRALINE; ANTIEMETIC AGENT; DOPAMINE 2 RECEPTOR; SEROTONIN ANTAGONIST;

ACUTE APPENDICITIS; ADULT; ANXIETY DISORDER; APPENDECTOMY; BEHAVIOR DISORDER; CASE REPORT; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE INCREASE; DRUG WITHDRAWAL; HOMICIDAL IDEATION; HUMAN; INSOMNIA; LEUKOCYTE COUNT; MALE; NAUSEA AND VOMITING; RACING THOUGHT; RESTLESSNESS; REVIEW; SUICIDAL IDEATION; THOUGHT DISORDER; THROMBOCYTE; AFFECT; AKATHISIA; DRUG ANTAGONISM; DRUG EFFECT; FANTASY; HOMICIDE; NAUSEA; PSYCHOLOGICAL ASPECT;

ADULT; AFFECT; AKATHISIA, DRUG-INDUCED; ANTIEMETICS; FANTASY; HOMICIDE; HUMANS; MALE; METOCLOPRAMIDE; NAUSEA; RECEPTORS, DOPAMINE D2; SEROTONIN ANTAGONISTS;

EID: 84856265254     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1016/j.psym.2011.02.001     Document Type: Review

References (40)

1. Shearer R.M., Bownes I.T., Curran P. Tardive akathisia and agitated depression during metoclopramide therapy. Acta Psychiatr Scand 1984, 70:428-431.
2. Ferrando S.J., Eisendrath S.J. Adverse neuropsychiatric effects of dopamine antagonist medications. Misdiagnosis in the medical setting. Psychosomatics 1991, 32:426-432.
3. Patterson D., Abell T., Rothstein R., et al. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 1999, 94:1230-1234.
4. Pasricha P.J., Pehlivanov N., Sugumar A., et al. Drug insight: From disturbed motility to disordered movement-a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol 2006, 3:138-148.
5. Albibi R., McCallum R.W. Metoclopramide: Pharmacology and clinical application. Ann Intern Med 1983, 98:86-95.
6. Sanger G.J. Translating 5-HT receptor pharmacology. Neurogastroenterol Motil 2009, 21:1235-1238.
7. Sanger G.J., Alpers D.H. Development of drugs for gastrointestinal motor disorders: Translating science to clinical need. Neurogastroenterol Motil 2008, 20:177-184.
8. Sanger G.J., King F.D. From metoclopramide to selective gut motility stimulants and 5-HT3 receptor antagonists. Drug Des Deliv 1988, 3:273-295.
9. Tonini M., Cipollina L., Poluzzi E., et al. Review article: Clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther 2004, 19:379-390.
10. Siddique S.M., Shariff N., Vesuwala N., et al. Metoclopramide as a possible cause of prolonged QT syndrome and torsade de pointes in a patient with heart failure and renal insufficiency. Ann Intern Med 2009, 150:502-504.
11. Claassen S., Zünkler B.J. Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology 2005, 74:31-36.
12. Ganzini L., Casey D.E., Hoffman W.F., et al. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 1993, 153:1469-1475.
13. Bottner R.K., Tullio C.J. Metoclopramide and depression. Ann Intern Med 1985, 103:482.
14. Adams C.D. Metoclopramide and depression. Ann Intern Med 1985, 103(6 Pt 1):960.
15. Weddington W.W., Banner A. Organic affective syndrome associated with metoclopramide: Case report. J Clin Psychiatry 1986, 47:208-209.
16. Feder R. Metoclopramide and depression. J Clin Psychiatry 1987, 48:38.
17. Rodgers C. Extrapyramidal side effects of antiemetics presenting as psychiatric illness. Gen Hosp Psychiatry 1992, 14:192-195.
18. Friend K.D., Young R.C. Late-onset major depression with delusions after metoclopramide treatment. Am J Geriatr Psychiatry 1997, 5:79-82.
19. Chow L.Y., Chung D., Leung V., et al. Suicide attempt due to metoclopramide-induced akathisia. Int J Clin Pract 1997, 51:330-331.
20. Marks D.H. Depression leading to suicide as an adverse effect of metoclopramide. Internet J Gastroenterol 2007, 5. number 2.
21. Kluge M., Schüssler P., Steiger A. Persistent generalized anxiety after brief exposure to the dopamine antagonist metoclopramide. Clin Psychiatry Neurosci 2007, 61:193-195.
22. Willner P. Dopamine and depression: a review of recent evidence. I. Empirical studies. Brain Res 1983, 287:211-224.
23. Barone P., Poewe W., Albrecht S., et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomized, double-blind, placebo-controlled trial. Lancet Neurol 2010, 9:573-580.
24. Leong G.B., Silva J.A. Neuroleptic-induced akathisia and violence: a review. J Forensic Sci 2003, 48:187-189.
25. Wright M.T. Antiemetics, akathisia, and pregnancy. Psychosomatics 2007, 48:461-466.
26. Marner L., Gillings N., Madsen K., et al. Brain imaging of serotonin 4 receptors in humans with [11C]SB207145-PET. Neuroimage 2010, 50:855-861.
27. Juurlink D.N., Mamdani M.M., Kopp A., et al. The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 2006, 163:813-821.
28. Koliscak L.P., Makela E.H. Selective serotonin reuptake inhibitor-induced akathisia. J Am Pharm Assoc (2003) 2009, 49:e28-e36. quiz e37-38.
29. Vandemergel X., Beukinga I., Nève P. Serotonin syndrome secondary to the use of sertraline and metoclopramide. Rev Med Brux 2000, 21:161-163.
30. Fisher A.A., Davis M.W. Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction. Ann Pharmacother 2002, 36:67-71.
31. Palop V., Jimenez M.J., Catalán C., et al. Acute dystonia associated with fluvoxamine-metoclopramide. Ann Pharmacother 1999, 33:382.
32. Leo R.J. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996, 57:449-454. Review.
33. Kuroki T., Nagao N., Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: A validity of the serotonin-dopamine hypothesis. Prog Brain Res 2008, 172:199-212.
34. Bennett A.C., Vila T.M. The role of ondansetron in the treatment of schizophrenia. Ann Pharmacol 2010, 44:1301-1306.
35. Lexi-Comp Online Drug Interaction Program http://www.uptodate.com/crlsql/interact/frameset.jsp.
36. Toovey S. Mefloquine neurotoxicity: a literature review. Travel Med Infect Dis 2009, 7:2-6.
37. Meyer R.E., Salzman C., Youngstrom E.A., et al. Suicidality and risk of suicide-definition, drug safety concerns, and a necessary target for drug development: a consensus statement. J Clin Psychiatry 2010, 71:1040-1046.
38. The American Psychiatric Association Practice Guideline for the Assessment and Treatment of the Patient with Suicidal Behaviors http://www.psychiatryonline.com/pracguide/pracguidechaptoc_14.aspx.
39. Ke C.L., Yen C.F., Chen C.C., et al. Obsessive-compulsive symptoms associated with clozapine and risperidone treatment: three case reports and review of the literature. Kaohsiung J Med Sci 2004, 20:295-300.
40. Sa A.R., Hounie A.G., Sampaio A.S., et al. Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol. Comprehensive Psychiatry 2009, 50:437-442.